- Data to date demonstrate high activity and favorable safety profile in Sézary syndrome, an aggressive form of cutaneous T-cell lymphoma (CTCL)
- International IPH4102 TELLOMAK Phase II clinical trial in advanced T-cell lymphoma (TCL) launched in June 2019
Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced the online publication in The Lancet Oncology of the results from the completed Phase I dose-escalation and expansion clinical trial of IPH4102 in advanced CTCL patients. The Lancet Oncology publication can be accessed here.
“We are very pleased with the publication of our IPH4102 Phase I results in a top tier, peer-reviewed medical journal,” said Pierre Dodion, Chief Medical Officer of Innate Pharma. “The specific mode of action of IPH4102 and its therapeutic potential in advanced T-cell lymphoma, now available to the broader Lymphoma community, demonstrate that targeting of KIR3DL2 by IPH4102 result in a combination of high and durable responses, a favorable safety profile and a substantial improvement in quality of life in Sézary syndrome. The IPH4102 Phase I study design included several innovative features including a smaller cohort of patients at the lowest dosages and intra-patient dose escalation which allowed for the optimization of the overall study execution. Based on these Phase I clinical trial data, we launched the TELLOMAK Phase II clinical trial in June 2019, which simultaneously could enable the registration of IPH4102 in Sézary syndrome and allow us to explore its potential in broader patient populations of T-cell lymphoma such as Mycosis fungoides (MF) and peripheral T-cell lymphoma (PTCL).”